drugset / Trial / NCT05682599
Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China
Phase 2
Unknown
300 enrolled
Shanghai Henlius Biotech
Henan Genuine Biotech Co., Ltd. · collabHuashan Hospital · collabShanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Individuals Infected with SARS-CoV-2 in China
Timeline
- Start
- 2023-01-06
- Primary completion
- 2023-04-15
- Completion
- 2023-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azvudine | Small molecule | 3 mg | Oral |
| Subject | Azvudine | Small molecule | 5 mg | Oral |